The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers

Conclusion: Camrelizumab and its combination are tolerable and appear to be efficient in treating numerous solid cancers. The combination therapy appears to have better efficacy with durable toxicity. However, these remain to be shown in future studies. Besides, baseline lactate dehydrogenase, programmed cell death ligand 1 (PD-L1) expression, tumor mutation burden, and the incidence of reactive cutaneous capillary endothelial proliferation may be efficacy predictors and need to be clarified in further studies.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research